Within our relatively small series, this suggests that there may be a subset of people with AD who have more intense neurodegeneration, reflected by NfL, which may, therefore, complement P-tau biomarkers as a predictor of cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.